Table 4:
Hazard ratio of non-atheromatous cardiovascular events associated with a double increase in baseline serum-free kynurenine level (mg/L).
| Free kynurenine (mg/L) | |
|---|---|
| Non-atheromatous cardiovascular events | |
| Unadjusted HR [95% CI]—P-value | 1.97 [1.7, 2.27]–<0.001 |
| Adjusted HR a [95% CI]—P-value | 1.36 [1.14, 1.61]–0.0007 |
| Adjusted HR b [95% CI]—P-value | 1.26 [1.03, 1.5]–0.02 |
| Adjusted HR c [95% CI]—P-value | 1.31 [1.09, 1.6]–0.003 |
a
Model adjusted for age at baseline, sex, high-sensitivity C-reactive protein, serum albumin, urea, diabetes, body mass index, smoking status, baseline estimated glomerular filtration rate, urine albumin- or protein-to-creatinine ratio, systolic blood pressure, prescriptions of diuretics, antihypertensive drugs, and antidiabetic drugs.
b
1 + serum-free tryptophan.
c
1 + serum-free indoxyl sulfate, indole-3-acetic acid and p-cresyl sulfate.